论文部分内容阅读
目的研究雷替曲塞联合奥沙利铂治疗晚期胃癌的疗效及安全性。方法选取苏州大学附属常州肿瘤医院2011年8月—2013年8月一线氟尿嘧啶类药物化疗失败后的23例晚期胃癌患者,予雷替曲塞联合奥沙利铂为二线方案化疗。观察患者的治疗效果。结果 23例患者中完全缓解(CR)1例(4.3%),部分缓解(PR)6例(26.8%),病情稳定(SD)8例(34.9%),疾病进展(PD)8例(34.9%),中位无进展生存时间3.5个月。18例患者产生毒副作用。结论雷替曲塞联合奥沙利铂二线治疗晚期胃癌疗效较好,毒副作用较小。
Objective To study the efficacy and safety of ralterexed and oxaliplatin in the treatment of advanced gastric cancer. Methods Twenty-three patients with advanced gastric cancer who failed chemotherapy with first-line fluorouracil in Changzhou Cancer Hospital affiliated to Soochow University from August 2011 to August 2013 were treated with raltetzine and oxaliplatin in the second-line regimen. Observe the patient’s treatment. Results Among the 23 patients, 1 was complete remission (CR), 6 were PR (26.8%), 8 (34.9%) were stable (SD), and 8 %), The median progression-free survival time 3.5 months. 18 patients had toxic side effects. Conclusion raltetmese combined with oxaliplatin second-line treatment of advanced gastric cancer has better curative effect and less side effects.